Logo image of RYTM

RHYTHM PHARMACEUTICALS INC (RYTM) Stock Fundamental Analysis

NASDAQ:RYTM - US76243J1051 - Common Stock

101.69 USD
-2.52 (-2.42%)
Last: 9/3/2025, 8:00:02 PM
101.69 USD
0 (0%)
After Hours: 9/3/2025, 8:00:02 PM
Fundamental Rating

3

Overall RYTM gets a fundamental rating of 3 out of 10. We evaluated RYTM against 542 industry peers in the Biotechnology industry. While RYTM seems to be doing ok healthwise, there are quite some concerns on its profitability. RYTM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RYTM had negative earnings in the past year.
RYTM had a negative operating cash flow in the past year.
In the past 5 years RYTM always reported negative net income.
In the past 5 years RYTM always reported negative operating cash flow.
RYTM Yearly Net Income VS EBIT VS OCF VS FCFRYTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -50.55%, RYTM is in line with its industry, outperforming 49.82% of the companies in the same industry.
Looking at the Return On Equity, with a value of -141.04%, RYTM is doing worse than 61.62% of the companies in the same industry.
Industry RankSector Rank
ROA -50.55%
ROE -141.04%
ROIC N/A
ROA(3y)-56.77%
ROA(5y)-52.61%
ROE(3y)-112.7%
ROE(5y)-88.62%
ROIC(3y)N/A
ROIC(5y)N/A
RYTM Yearly ROA, ROE, ROICRYTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Gross Margin of RYTM (89.25%) is better than 90.96% of its industry peers.
RYTM's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RYTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.35%
GM growth 5YN/A
RYTM Yearly Profit, Operating, Gross MarginsRYTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
RYTM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RYTM has more shares outstanding
RYTM has a better debt/assets ratio than last year.
RYTM Yearly Shares OutstandingRYTM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RYTM Yearly Total Debt VS Total AssetsRYTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 11.84 indicates that RYTM is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.84, RYTM belongs to the top of the industry, outperforming 87.45% of the companies in the same industry.
A Debt/Equity ratio of 0.79 indicates that RYTM is somewhat dependend on debt financing.
RYTM has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: RYTM underperforms 74.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 11.84
ROIC/WACCN/A
WACC9.84%
RYTM Yearly LT Debt VS Equity VS FCFRYTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.79 indicates that RYTM has no problem at all paying its short term obligations.
RYTM has a Current ratio of 2.79. This is in the lower half of the industry: RYTM underperforms 66.79% of its industry peers.
A Quick Ratio of 2.64 indicates that RYTM has no problem at all paying its short term obligations.
The Quick ratio of RYTM (2.64) is worse than 66.05% of its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.64
RYTM Yearly Current Assets VS Current LiabilitesRYTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.11% over the past year.
RYTM shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.34%.
RYTM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 245.69% yearly.
EPS 1Y (TTM)33.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
Revenue 1Y (TTM)22.34%
Revenue growth 3Y245.69%
Revenue growth 5YN/A
Sales Q2Q%66.8%

3.2 Future

Based on estimates for the next years, RYTM will show a very strong growth in Earnings Per Share. The EPS will grow by 31.60% on average per year.
Based on estimates for the next years, RYTM will show a very strong growth in Revenue. The Revenue will grow by 61.64% on average per year.
EPS Next Y32.82%
EPS Next 2Y24.33%
EPS Next 3Y30.46%
EPS Next 5Y31.6%
Revenue Next Year45.4%
Revenue Next 2Y54.2%
Revenue Next 3Y62.52%
Revenue Next 5Y61.64%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RYTM Yearly Revenue VS EstimatesRYTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RYTM Yearly EPS VS EstimatesRYTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RYTM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RYTM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYTM Price Earnings VS Forward Price EarningsRYTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYTM Per share dataRYTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

RYTM's earnings are expected to grow with 30.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.33%
EPS Next 3Y30.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RYTM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (9/3/2025, 8:00:02 PM)

After market: 101.69 0 (0%)

101.69

-2.52 (-2.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners94.81%
Inst Owner Change0.48%
Ins Owners0.67%
Ins Owner Change0.44%
Market Cap6.75B
Analysts87
Price Target113.29 (11.41%)
Short Float %7.38%
Short Ratio6.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.01%
Min EPS beat(2)-13.18%
Max EPS beat(2)-8.85%
EPS beat(4)2
Avg EPS beat(4)-2.55%
Min EPS beat(4)-13.18%
Max EPS beat(4)11.07%
EPS beat(8)4
Avg EPS beat(8)-1.33%
EPS beat(12)7
Avg EPS beat(12)1.68%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)1
Avg Revenue beat(2)-5.75%
Min Revenue beat(2)-20.47%
Max Revenue beat(2)8.98%
Revenue beat(4)3
Avg Revenue beat(4)-1.17%
Min Revenue beat(4)-20.47%
Max Revenue beat(4)8.98%
Revenue beat(8)3
Avg Revenue beat(8)-2.24%
Revenue beat(12)5
Avg Revenue beat(12)0.92%
Revenue beat(16)8
Avg Revenue beat(16)14.5%
PT rev (1m)7.17%
PT rev (3m)40.15%
EPS NQ rev (1m)-4.8%
EPS NQ rev (3m)-10.1%
EPS NY rev (1m)-6.67%
EPS NY rev (3m)-8.64%
Revenue NQ rev (1m)7.67%
Revenue NQ rev (3m)6.08%
Revenue NY rev (1m)4.96%
Revenue NY rev (3m)4.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 43.22
P/FCF N/A
P/OCF N/A
P/B 50.56
P/tB 52.84
EV/EBITDA N/A
EPS(TTM)-3.01
EYN/A
EPS(NY)-2.04
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS2.35
BVpS2.01
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.55%
ROE -141.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.25%
FCFM N/A
ROA(3y)-56.77%
ROA(5y)-52.61%
ROE(3y)-112.7%
ROE(5y)-88.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.35%
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.64
Altman-Z 11.84
F-Score4
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
EPS Next Y32.82%
EPS Next 2Y24.33%
EPS Next 3Y30.46%
EPS Next 5Y31.6%
Revenue 1Y (TTM)22.34%
Revenue growth 3Y245.69%
Revenue growth 5YN/A
Sales Q2Q%66.8%
Revenue Next Year45.4%
Revenue Next 2Y54.2%
Revenue Next 3Y62.52%
Revenue Next 5Y61.64%
EBIT growth 1Y56.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.27%
EBIT Next 3Y28.6%
EBIT Next 5YN/A
FCF growth 1Y32.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.04%
OCF growth 3YN/A
OCF growth 5YN/A